PDACPhase 1/2NCT06922591
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
A Phase 1/2 study testing TNG462, RMC-9805 and RMC-6236 in people with PDAC and PDAC - Pancreatic Ductal Adenocarcinoma, run by Tango Therapeutics, Inc. at 18 sites in United States.
Trial summary
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC
- What is being tested?
- TNG462, RMC-9805 and RMC-6236
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 183 participants
- Where
- 18 sitesUnited States
- Study dates
- 31 May 2025to Dec 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Is ≥18 years of age at the time of signature of the main study ICF.
- Has an ECOG PS of 0 or 1.
- Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
- Arms A and B only: Has a tumor with a RAS mutation
- Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
- Has received prior standard therapy
Show all 12Show fewer
- Arms A and B only: Must not have received prior RAS-targeted therapy
- Has evidence of measurable disease based on RECIST v1.1.
- Adequate organ function
- Must be able to swallow tablets.
- Negative pregnancy test at screening
- Written informed consent must be obtained according to local guidelines
Who cannot join
- Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor
- Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805
- Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine/nab-paclitaxel (Arm D) or their excipients
- Has uncontrolled intercurrent illness that will limit compliance with the study requirements.
- Has an active infection requiring systemic therapy.
- Is currently participating in or has planned concurrent participation in a study of another investigational agent or device.
Show all 18Show fewer
- Has impairment of GI function or disease that may significantly alter the absorption of the oral medications
- Has known or suspected active or untreated CNS metastases associated with progressive neurological symptoms
- Has current active liver disease from any cause
- Is known to be HIV positive, unless all the following criteria are met:
- CD4+ count ≥300/µL.
- Undetectable viral load.
- Receiving highly active antiretroviral therapy
- Has clinically relevant cardiovascular disease
- History of or presence of active interstitial lung disease
- Is a female patient who is pregnant or lactating
- Is unwilling or unable to comply with the scheduled visits, study treatment administration plan, laboratory tests or other study procedures and study restrictions.
- Has a prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion may affect the safety of the patient or impair the ability to assess study results
Trial locations and contacts
18 sites in 1 country. Contact the study team or a site near you to ask about taking part.
18 sites in 1 country
United States18 sites, 18 recruiting
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Harshabad Singh, MD
- Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Kimberly Perez, MD
- Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599-7305
Shetal Patel, MD, PhD
- Recruiting
Northwestern Memorial Hospital
Chicago, Illinois, 60611-2908
Bilal Anouti, MD
- Recruiting
Sarah Cannon Research Institute Denver
Denver, Colorado, 80218
Gerald Falchook, MD, MS
- Recruiting
NEXT Oncology
Fairfax, Virginia, 22031
Alexander Spira, MD, PhD
- Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030
Jordi Rodon Ahnert, MD
- Recruiting
University of Indiana
Indianapolis, Indiana, 46202
Anita Turk, MD
- Recruiting
University of Iowa Health Care
Iowa City, Iowa, 52242
Naomi Fei, MD, MS
- Recruiting
NEXT Dallas
Irving, Texas, 74039
Siraj Sen, MD
- Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224
Hani Babiker, MD
- Recruiting
NYU Langone Health
New York, New York, 10016
Kristen Spencer, DO, MPH
- Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, 11065
Eileen O'Reilly, MD
- Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, 68124
Joel Michalski, MD, PhD
- Recruiting
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905-0001
Kaushal Parikh, MD
- Recruiting
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, 84112
Vaia Florou, MD, MS
- Recruiting
Mayo Clinic Scottsdale
Scottsdale, Arizona, 85259-5452
Mitesh Borad, MD
- Recruiting
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007
Marcus Noel, MD
About this study
Official title: A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Read the detailed description
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel.
For the RAS inhibitor arms, the study will be conducted in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC). For the chemotherapy specific arms, the study will be conducted in patients with MTAP loss locally advanced or metastatic PDAC. The entire study (all arms) will be conducted in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual Arms in the dose expansion phase may open once the MTD and/or RD(s) has been determined for the corresponding combination in the dose escalation phase of the study.
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer
- Being tested
- TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel
- Keywords
- PRMT5 inhibitor, RAS G12D, Multi RAS, RMC-9805, RMC-6236, Thoracic, Targeted therapy
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TNG462Drug
MTA cooperative PRMT5 inhibitor
RMC-9805Drug
RAS(ON) G12D selective covalent inhibitor
RMC-6236Drug
RAS(ON) multi-selective inhibitor
mFOLFIRINOXDrug
Chemotherapy
gemcitabine/nab-paclitaxelDrug
Chemotherapy
| Study group | Role | What they receive |
|---|---|---|
| Dose Escalation 1A | Experimental | Escalating oral doses of TNG462 in combination with oral RMC-6236 Receives: Drug: TNG462; Drug: RMC-6236 |
| Dose escalation 1B | Experimental | Escalating oral doses of TNG462 in combination with oral RMC-9805 Receives: Drug: TNG462; Drug: RMC-9805 |
| Dose Expansion 2A | Experimental | Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236 Receives: Drug: TNG462; Drug: RMC-6236 |
| Dose Expansion 2B | Experimental | Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805 Receives: Drug: TNG462; Drug: RMC-9805 |
| Experimental: Dose Escalation 1C | Experimental | Escalating doses of TNG462 in combination with mFOLFIRINOX Receives: Drug: TNG462; Drug: mFOLFIRINOX |
| Experimental: Dose Escalation 1D | Experimental | Escalating doses of TNG462 in combination with gemcitabine/nab-paclitaxel Receives: Drug: TNG462; Drug: gemcitabine/nab-paclitaxel |
| Experimental: Dose Expansion 2C | Experimental | Expansion arm at the RDE(s) of TNG462 in combination with mFOLFIRINOX Receives: Drug: TNG462; Drug: mFOLFIRINOX |
| Experimental: Dose Expansion 2D | Experimental | Expansion arm at the RDE(s) of TNG462 in combination with gemcitabine/nab-paclitaxel Receives: Drug: TNG462; Drug: gemcitabine/nab-paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Phase 1: Maximum Tolerated Dose
To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Measured: 21 days
Phase 1: Maximum Tolerated Dose
To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel
Measured: 28 days
Phase 2: Combination Anti-neoplastic Activity
To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1
Measured: 12 weeks
Secondary outcomes (9)
Phase 1: Combination Anti-neoplastic Activity
To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX, or gemcitabine/nab paclitaxel using RECIST 1.1
Measured: 12 weeks
Phase 1 and 2: Tmax of TNG462 and in Combination
To characterize the Tmax of TNG462 in combination with RMC-6236 or RMC-9805
Measured: 21 days
Phase 1 and 2: Tmax of TNG462 and in Combination
To characterize the Tmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel
Measured: 28 days
Phase 1 and 2: Cmax of TNG462 and in Combination
To characterize the Cmax of TNG462 in combination with RMC-6236 or RMC-9805
Measured: 21 days
Phase 1 and 2: Cmax of TNG462 and in Combination
To characterize the Cmax of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel
Measured: 28 days
Phase 1 and 2: AUC of TNG462 and in Combination
To characterize the AUC of TNG462 and in combination with RMC-6236 or RMC-9805
Measured: 21 days
Phase 1 and 2: AUC of TNG462 and in Combination
To characterize the AUC of TNG462 in combination with mFOLFIRINOX, or gemcitabine/nab-paclitaxel
Measured: 28 days
Phase 1 and 2 Adverse Event Profile
To determine the safety and tolerability of TNG462 in combination with RMC-6236 or RMC-9805
Measured: 21 days
Phase 1 and 2 Adverse Event Profile
To determine the safety and tolerability of TNG462 in combination with mFOLFIRINOX or gemcitabine nab-paclitaxel
Measured: 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Apr 2025
- Study start31 May 2025
- Primary completionJun 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PDACStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- Dose escalation of TNG462 + RMC-9805, TNG462 + RMC-6236, TNG462 + mFOLFIRINOX and TNG462 + gemcitabine/nab-paclitaxel, followed by expansion of each combination in MTAP loss and RAS mutant PDAC and NSCLC
- Masking
- None (open label)
- Enrolment
- 183 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tango Therapeutics, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Revolution Medicines, Inc.
- Responsible party
- Sponsor
- Investigators
- Maxim Pimpkin, MD, PhD, Study director, Tango Therapeutics, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06922591
- Sponsor's protocol ID
- TNG462-C102
- Status last verified
- May 2026
- First submitted
- 28 Mar 2025
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation
- ClinicalTrials.gov ID
- NCT06922591
- Acronym / sponsor ID
- TNG462-C102
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer
- Keywords
- PRMT5 inhibitor, RAS G12D, Multi RAS, RMC-9805, RMC-6236, Thoracic, Targeted therapy
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 183 participants (estimated)
- Lead sponsor
- Tango Therapeutics, Inc.Industry (pharma, biotech, devices)
- Collaborators
- Revolution Medicines, Inc.
- Study start
- 31 May 2025 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 10 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase.
Detailed description
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel.
For the RAS inhibitor arms, the study will be conducted in patients with MTAP loss and RAS mutant metastatic pancreatic adenocarcinoma (PDAC) or locally advanced or metastatic non-small cell lung cancer (NSCLC). For the chemotherapy specific arms, the study will be conducted in patients with MTAP loss locally advanced or metastatic PDAC. The entire study (all arms) will be conducted in 2 parts: Phase 1 (dose escalation) and Phase 2 (dose expansion).
Individual Arms in the dose expansion phase may open once the MTD and/or RD(s) has been determined for the corresponding combination in the dose escalation phase of the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 8
- Model description
- Dose escalation of TNG462 + RMC-9805, TNG462 + RMC-6236, TNG462 + mFOLFIRINOX and TNG462 + gemcitabine/nab-paclitaxel, followed by expansion of each combination in MTAP loss and RAS mutant PDAC and NSCLC
| Arm | Type | Receives |
|---|---|---|
| Dose Escalation 1A | Experimental | Drug: TNG462, Drug: RMC-6236Escalating oral doses of TNG462 in combination with oral RMC-6236 |
| Dose escalation 1B | Experimental | Drug: TNG462, Drug: RMC-9805Escalating oral doses of TNG462 in combination with oral RMC-9805 |
| Dose Expansion 2A | Experimental | Drug: TNG462, Drug: RMC-6236Expansion arm at the RDE(s) of oral TNG462 in combination with oral RMC-6236 |
| Dose Expansion 2B | Experimental | Drug: TNG462, Drug: RMC-9805Expansion arm at the RDE(s) of oral TNG462 in combination with oralRMC-9805 |
| Experimental: Dose Escalation 1C | Experimental | Drug: TNG462, Drug: mFOLFIRINOXEscalating doses of TNG462 in combination with mFOLFIRINOX |
| Experimental: Dose Escalation 1D | Experimental | Drug: TNG462, Drug: gemcitabine/nab-paclitaxelEscalating doses of TNG462 in combination with gemcitabine/nab-paclitaxel |
| Experimental: Dose Expansion 2C | Experimental | Drug: TNG462, Drug: mFOLFIRINOXExpansion arm at the RDE(s) of TNG462 in combination with mFOLFIRINOX |
| Experimental: Dose Expansion 2D | Experimental | Drug: TNG462, Drug: gemcitabine/nab-paclitaxelExpansion arm at the RDE(s) of TNG462 in combination with gemcitabine/nab-paclitaxel |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Is ≥18 years of age at the time of signature of the main study ICF.
- Has an ECOG PS of 0 or 1.
- Has a tumor with loss of MTAP protein or bi-allelic deletion of the MTAP gene
- Arms A and B only: Has a tumor with a RAS mutation
- Pathologically documented metastatic PDAC or locally advanced, recurrent or metastatic NSCLC
Key exclusion criteria (18 listed)
- Has received prior treatment with a PRMT5 inhibitor, or MAT2A inhibitor
- Arms A and B only: Prior enrollment in any phase 3 clinical trial of RMC-6236 or RMC-9805
- Known allergy, hypersensitivity or intolerance to TNG462 (all arms), RMC-6236 Arm A), RMC-9805 (Arm B), mFOLFIRINOX (Arm C), gemcitabine/nab-paclitaxel (Arm D) or their excipients
- Has uncontrolled intercurrent illness that will limit compliance with the study requirements.
- Has an active infection requiring systemic therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TNG462MTA cooperative PRMT5 inhibitor | Drug | Dose Escalation 1A, Dose Expansion 2A, Dose Expansion 2B, Dose escalation 1B, Experimental: Dose Escalation 1C, Experimental: Dose Escalation 1D, Experimental: Dose Expansion 2C, Experimental: Dose Expansion 2D |
| RMC-9805RAS(ON) G12D selective covalent inhibitor | Drug | Dose Expansion 2B, Dose escalation 1B |
| RMC-6236RAS(ON) multi-selective inhibitor | Drug | Dose Escalation 1A, Dose Expansion 2A |
| mFOLFIRINOXChemotherapy | Drug | Experimental: Dose Escalation 1C, Experimental: Dose Expansion 2C |
| gemcitabine/nab-paclitaxelChemotherapy | Drug | Experimental: Dose Escalation 1D, Experimental: Dose Expansion 2D |
Primary outcome
Phase 1: Maximum Tolerated Dose
Time frame: 21 days
To determine the MTD and RD(s) of TNG462 in combination with RMC-6236 or RMC-9805
Phase 1: Maximum Tolerated Dose
Time frame: 28 days
To determine the MTD and RD(s) of TNG462 in combination with mFOLFIRINOX or gemcitabine/nab-paclitaxel
Phase 2: Combination Anti-neoplastic Activity
Time frame: 12 weeks
To assess preliminary evidence of antineoplastic activity of TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel using RECIST 1.1
9 secondary outcomes
Phase 1: Combination Anti-neoplastic Activity
Time frame: 12 weeks
Phase 1 and 2: Tmax of TNG462 and in Combination
Time frame: 21 days
Phase 1 and 2: Tmax of TNG462 and in Combination
Time frame: 28 days
Phase 1 and 2: Cmax of TNG462 and in Combination
Time frame: 21 days
Phase 1 and 2: Cmax of TNG462 and in Combination
Time frame: 28 days
Phase 1 and 2: AUC of TNG462 and in Combination
Time frame: 21 days
Phase 1 and 2: AUC of TNG462 and in Combination
Time frame: 28 days
Phase 1 and 2 Adverse Event Profile
Time frame: 21 days
Phase 1 and 2 Adverse Event Profile
Time frame: 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Oct 2026.
Related trials for PDAC
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC), G12D Mutated KRAS
RecruitingPhase 3
Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Maxim Pimpkin, MD, PhD study director
Tango Therapeutics, Inc.
18 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing TNG462, RMC-9805 and RMC-6236 in people with PDAC and PDAC - Pancreatic Ductal Adenocarcinoma, run by Tango Therapeutics, Inc. at 18 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 23 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 18 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Maxim Pimpkin, MD, PhD (857-320-4899, clinicaltrials@tangotx.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Phase 1: Maximum Tolerated Dose (time frame: 21 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2026.